Biomarker Research for Personalized Medicine
- Conditions
- Hematologic Neoplasms
- Registration Number
- NCT01488591
- Lead Sponsor
- Inje University
- Brief Summary
The aim of this study :
1. Through the study of genes of protein, transporter, translator and epigenome investigating the effect of anti-cancer treatment or the key factor of the MDR (Multidrug resistance) on the blood cancer patients who are under the anti-cancer sork treatment
2. Giving a service of anticancer medicine therapeutic drug monitoring (TDM) and genotyping
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 1000
Inclusion Criteria
- Korean
- Clinical diagnosis of Hematologic neoplasms
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How do transporter proteins and epigenetic factors contribute to multidrug resistance in hematologic neoplasms during anti-cancer treatment?
What biomarkers are identified in NCT01488591 for predicting therapeutic response to anti-cancer drugs in blood cancer patients?
How does therapeutic drug monitoring (TDM) in NCT01488591 compare to standard-of-care dosing in improving treatment outcomes for leukemia or lymphoma?
What adverse events are linked to anti-cancer therapies in hematologic cancers, and how does pharmacogenomic data from NCT01488591 inform their management?
Are there potential synergies between MDR inhibitors and targeted therapies in hematologic neoplasms as explored in NCT01488591?
Trial Locations
- Locations (1)
Inje University
🇰🇷Busan, Korea, Republic of